Kevin Kunzmann

Though the combination heart failure therapy did provide overall benefit versus ramipril in post-heart attack patients, the rate of events reduced was not considered significant.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

Research from ARVO 2021 details the complexities and current challenges faced when attempting to address the burden of diabetic eye disease while the number of patients with diabetes in the US continues to balloon.

Climate change health experts Poune Saberi, MD, and Alan S. Greenglass, MD, join Lungcast for a timely discussion on environmental health issues.

Research at ARVO 2021 highlighted a gamut of interplaying diabetes and vision loss risk factors, and even treatments for both. But experts depict a referral and care process that lacks whole diabetes care.

A podcast interview with study author Paul Yang, MD, PhD, on the current research and future implementation of the agent.

A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

The innovative technology is associated with significantly improved time to tear breakup, meibum quality, and improved inflammatory markers.

A new cross-sectional survey assessment shows patients more severe disease report worse survey outcomes on emotional wellbeing and social activity.

A study out of Boston observes little to no difference in previous biologic prescription and worsened odds of infection nor death during the pandemic.

An assessment of real-world registry data suggest the biologic provides significant benefit outside of clinical trials.

A network meta-analysis shows favorability with dupilumab and abrocitinib in efficacy and safety outcomes among adults and adolescents.

Lawrence Eichenfield, MD, discusses future prescribing plans and safety assessment for the topical JAK 1/2 inhbitor.

New cross-sectional survey data suggest quality-of-life and psychological outcomes may differ in the most common chronic skin disease patient populations.

The investigative topical cream benefits adolescent and adult skin clearance and itch. A study author discusses keeping it available to patients if it reaches the market.

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.

Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.

A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.

A thrombosis expert details cerebral venous thrombosis, the side effect reported in a half-dozen women administered the Johnson & Johnson vaccine.

FDA, CDC recommended halting use of the one-shot vaccine at all federal sites.

New data show reduced risk of mortality, and clinical savings upward of $100,000, are linked to sometimes inaccessible substance use disorder therapies.

The pandemic forced practices to consider more virtual screening and care. A dermatologist shares perspective on what's been working as telemedicine practice.